COMMUNIQUÉS West-GlobeNewswire

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
30/04/2026
Proven immunology-focused executive and physician-scientist who has led companies from inception to IPO, driven multiple regulatory approvals, and helped build multi-billion-dollar therapeutic portfolios BOSTON, April [...]
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
30/04/2026
EchoSolv AS deployed into Mount Sinai Health System, a leading US health system in New York Mount Sinai Health System comprises seven hospitals, over 400 outpatient practices and +3,760 beds Mount Sinai Fuster Heart [...]
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
30/04/2026
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a [...]
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
30/04/2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for [...]
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
30/04/2026
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%; non-GAAP income [...]
The Ensign Group Acquires Real Estate and Expands Operations in Texas
30/04/2026
SAN JUAN CAPISTRANO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
Emergent BioSolutions Reports First Quarter 2026 Financial Results
30/04/2026
First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% [...]
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
30/04/2026
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 [...]
TLX101-Px (Pixlumi®) MAA Accepted in Europe
30/04/2026
MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA) filed in Europe [...]
DBV Technologies publie ses résultats financiers du 1er trimestre 2026
30/04/2026
Châtillon, France, 30 avril 2026 DBV Technologies publie ses résultats financiers du 1er trimestre 2026 Trésorerie et équivalents de trésorerie de 229 millions de dollars au 31 mars 2026, portant l’horizon de trésorerie [...]
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
30/04/2026
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to [...]
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
30/04/2026
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the [...]
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
30/04/2026
Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment Fully enrolled first cohort is assessing the infectivity of [...]
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
30/04/2026
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
30/04/2026
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief [...]
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
30/04/2026
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a [...]
Alvotech Announces a Change in its Executive Team
30/04/2026
REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that [...]
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/04/2026
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , société pharmaceutique spécialisée en phase avancée de développement et [...]
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
30/04/2026
Ghent, Belgium – April 30, 2026 – Confo Therapeutics , a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a Phase 2a clinical [...]

Pages